Re: Multistem and Coronoa Virus
Still not convinced they can currently supply enough product. Can't get MASTERS 2 sites up and running, can't start trauma study. Manufacturing has to be #1 priority. Followed closely by partnering Europe.
On the horizon is the 'going it alone in USA decision'. They need to think carefully about that. Some of you may be in PTLA. Similar scenario. First in class, large unmet need, critical care hospital product, high price tag. Slow uptake. Takes a lot of money to launch in hopital market, even if you have guidelines, pharmacoeconomics, etc. in your pocket. Commercial hires in US will be key. Need to be realistic.